We are addressing the continuing unmet needs of patients with cardiovascular disease through:
in PDE9 and CaMKII inhibition
of CV experts and industry veterans with track records of success
driven by in-house drug discovery and the office of strategy
with key strategics and investors, including a $300 million investment from Bain Capital to support current programs and pipeline growth
in 2022, positioning us for rapid growth across multiple indications
in PDE9 and CaMKII inhibition
of CV experts and industry veterans with track records of success
driven by in-house drug discovery and the office of strategy
with key strategics and investors, including a $300 million investment from Bain Capital to support current programs and pipeline growth
in 2022, positioning us for rapid growth across multiple indications
PDE9 inhibition presents an opportunity to develop:
CaMKII plays a critical role in cardiac function but has been a challenging target to inhibit.
* CPVT, catecholaminergic polymorphic ventricular tachycardia
**Afib, atrial fibrillation
To request additional information or contact us, please fill out the contact form.
78 Blanchard Road
Suite 200
Burlington, MA 01803, USA
Info@cardurion.com
617-863-8088
Cardurion Pharmaceuticals KK
26-1, Muraoka-Higashi 2-chome,
Fujisawa, Kanagawa 251-8555, Japan
Email: info@cardurion.com
©2023 Cardurion Pharmaceuticals. All rights reserved.
This site uses cookies and third-party scripts to provide certain services. View Privacy Policy
